|65.19|| +0.62 / +0.96%|
PAREXEL International Corp. is a biopharmaceutical services company. It provides clinical research, medical communications, consulting, commercialization and informatics, and technology services to pharmaceutical, biotechnology, and medical device industries. The company operates through the following segments: Clinical Research Services, PAREXEL Consulting Services and PAREXEL Informatics. The Clinical Research Services segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, date management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, clinical pharmacology, and related medical affiairs, patient recruitment and investigator site services. The PAREXEL Consulting Services segment provides technical expertise and advice in drug development, regulatory affairs, and good manufacturing practice compliance consulting. The PAREXEL Informatics segment provides information technology solutions designed to improve client's product development processes. PAREXEL International was founded by Josef H. von Rickenbach and Anne B. Sayigh in 1983 and is headquartered in Waltham, MA.
|Josef H. von Rickenbach||Chairman & Chief Executive Officer|
|Mark A. Goldberg||President & Chief Operating Officer|
|Emma Reeve||Chief Financial Officer, VP & Controller|
|Roland Andersson||Senior Vice President-Clinical Research Services|
|Sy Pretorius||Chief Scientific Officer & Vice President|